{"id":925297,"date":"2026-01-08T07:40:46","date_gmt":"2026-01-08T12:40:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/"},"modified":"2026-01-08T07:40:46","modified_gmt":"2026-01-08T12:40:46","slug":"zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/","title":{"rendered":"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CELEBRATION, Fla., Jan.  08, 2026  (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra\u2019s executive leadership team will present at the J.P. Morgan 44<sup>th<\/sup> Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT.<\/p>\n<p align=\"justify\">Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7KNOpAhHuqa2NwVk56V1HQOvFwmKHJrDXVXlkPhHeemNDjcRMK60S5SU2xdDqCRpmVfMM_LBzxs7x7HxzdZO4Auyu7NpwWDJC3nKHrqmDU3q-aBysmgBgc30qHZRVradVOvCyGTcnfYf2Ju2uRnyCA==\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d page in the Investor Relations section of Zevra\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_l0BaqFWPHFhbrNnu78GldbdogM2RtqnCn0p-3Wj_q1l8O0lBMZAJWmUqlTbepm2tizgIOH9jGb9lFdjHjGFwHcKyGGp7m8vZR6RjyggrM-FCKpp5XOskPvmsS6zFgD\" rel=\"nofollow\" target=\"_blank\">investors.zevra.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Zevra Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company\u2019s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DTXubRUHJ7_TjErvDLoVGMjGldPUCxzchQW4qMbAZbphID4xu--kS-MTuEt8RCh_lWT1pDK-CZenKHbgocai9A==\" rel=\"nofollow\" target=\"_blank\">www.zevra.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B8FbHvXPry_T9h3zx8bG_2jrWmqDph3_Ielu_Uy8j2C6iOMiS2xFsTXeZnmxcznPlA0HT_GTrl78Fr-2YESTgs2pJmuN-ztx-AKNm-tNU_IzTGske5QFHmBrLKJY1Nl4weDz7XgJ9oAxucCXwLxjH13MserPmBgS8v2vnibgAt2U69QtV3aR2KXudroPH5lOgue9vpFF8l8cVsNGcVg0bPJPuRrlxy0xGKZ7GQT7YouiNdvPF5vTwnTJx_byJnkopTAXsnxcAh2qgvVB4Mv9wcRC5NZr4Uax9eDylJ5mXOw=\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R-e13ie9Mvv7X07BPK8BDqN9ASRm22ZOEx9TpZmNmF9NSlOOLqStdTA6dtyaJxXuiJhoS59Ro8CTog9-ai1O2BSAdQkJXC92dZ3apLvUaadYLnXiltK_d_9PABln0yFpB_UmYg4HOTEgkdtOQ5NifHCeZqUVdawXPAF3lCSJCCZj01Oh4uFky6LKHXE2gVfWbueEIlOpFaGybfc5kcAW997HEdiQNYSBf-StvEWoByItSIOgo_Qwgizr-nR80VV1oddI8UD5vKCXNB_28gTehg==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Caution Concerning Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the \u201cRisk Factors\u201d section of Zevra\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra\u2019s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Nichol Ochsner\u00a0<br \/>+1 (732) 754-2545\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EIJnL4K6GuYe-5ql5d-1YwwgZpi31JReMmQa7SrTfXC1Acn4hy7bKciTrm-LmYtKlnqBGyGvDTdkz5rptR5PUIJdBO4e25ST8CeFinNkA34=\" rel=\"nofollow\" target=\"_blank\">nochsner@zevra.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Julie Downs<br \/>+1 (508) 246-3230\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g0fK7vNoWW4d7fuUzhwXv2-mXTwDS4P-ZKGLMx0qyeQWEnQpvsZV_qSfUahx48CLWpzE2VMDIIoi344yoEW1Syv8gbrSIUn9Alu1zqmrz_k=\" rel=\"nofollow\" target=\"_blank\">jdowns@zevra.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmMxOWExNDgtYzczOS00NDNmLThiZTEtZTliZDgwNTliMWNlLTEwMjkzMjgtMjAyNi0wMS0wOC1lbg==\/tiny\/Zevra-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra\u2019s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the \u201cEvents &amp; Presentations\u201d page in the Investor Relations section of Zevra\u2019s website at investors.zevra.com. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925297","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra\u2019s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the \u201cEvents &amp; Presentations\u201d page in the Investor Relations section of Zevra\u2019s website at investors.zevra.com. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with &hellip; Continue reading &quot;Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T12:40:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference\",\"datePublished\":\"2026-01-08T12:40:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/\"},\"wordCount\":482,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/\",\"name\":\"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=\",\"datePublished\":\"2026-01-08T12:40:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - Market Newsdesk","og_description":"CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) &#8212; Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra\u2019s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the \u201cEvents &amp; Presentations\u201d page in the Investor Relations section of Zevra\u2019s website at investors.zevra.com. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with &hellip; Continue reading \"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-08T12:40:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference","datePublished":"2026-01-08T12:40:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/"},"wordCount":482,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/","name":"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=","datePublished":"2026-01-08T12:40:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMTgwNiM3MzUwMTA2IzIwMTc3NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zevra-therapeutics-to-present-at-the-j-p-morgan-44th-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925297"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925297\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}